{
    "root": "205185eb-7430-4575-9bf2-9ed53df88590",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "KEYTRUDA",
    "value": "20250319",
    "ingredients": [
        {
            "name": "pembrolizumab",
            "code": "DPT0O3T46P"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "keytruda programmed death receptor-1 ( pd-1 ) -blocking antibody indicated : melanoma treatment patients unresectable metastatic melanoma . ( 1.1 ) adjuvant treatment adult pediatric ( 12 years older ) patients stage iib , iic , iii melanoma following complete resection . ( 1.1 ) non-small cell lung cancer ( nsclc ) combination pemetrexed platinum chemotherapy , first-line treatment patients metastatic nonsquamous nsclc , egfr alk genomic tumor aberrations . ( 1.2 ) combination carboplatin either paclitaxel paclitaxel protein-bound , first-line treatment patients metastatic squamous nsclc . ( 1.2 ) single agent first-line treatment patients nsclc expressing pd-l1 [ tumor proportion score ( tps ) ≥1 % ] determined fda-approved test , egfr alk genomic tumor aberrations , : stage iii patients candidates surgical resection definitive chemoradiation , metastatic . ( 1.2 , 2.1 ) single agent treatment patients metastatic nsclc whose tumors express pd-l1 ( tps ≥1 % ) determined fda-approved test , disease progression platinum-containing chemotherapy . patients egfr alk genomic tumor aberrations disease progression fda-approved therapy aberrations prior receiving keytruda . ( 1.2 , 2.1 ) treatment patients resectable ( tumors ≥4 cm node positive ) nsclc combination platinum-containing chemotherapy neoadjuvant treatment , continued single agent adjuvant treatment surgery . ( 1.2 ) single agent , adjuvant treatment following resection platinum-based chemotherapy adult patients stage ib ( t2a ≥4 cm ) , ii , iiia nsclc . ( 1.2 ) malignant pleural mesothelioma ( mpm ) combination pemetrexed platinum chemotherapy , first-line treatment adult patients unresectable advanced metastatic mpm . ( 1.3 ) head neck squamous cell cancer ( hnscc ) combination platinum fu first-line treatment patients metastatic unresectable , recurrent hnscc . ( 1.4 ) single agent first-line treatment patients metastatic unresectable , recurrent hnscc whose tumors express pd-l1 [ combined positive score ( cps ) ≥1 ] determined fda-approved test . ( 1.4 , 2.1 ) single agent treatment patients recurrent metastatic hnscc disease progression platinum-containing chemotherapy . ( 1.4 ) classical hodgkin lymphoma ( chl ) treatment adult patients relapsed refractory chl . ( 1.5 ) treatment pediatric patients refractory chl , chl relapsed 2 lines therapy . ( 1.5 ) primary mediastinal large b-cell lymphoma ( pmbcl ) treatment adult pediatric patients refractory pmbcl , relapsed 2 prior lines therapy . ( 1.6 ) limitations : keytruda recommended treatment patients pmbcl require urgent cytoreductive therapy . urothelial cancer combination enfortumab vedotin , treatment adult patients locally advanced metastatic urothelial cancer . ( 1.7 ) single agent treatment patients locally advanced metastatic urothelial carcinoma : eligible platinum-containing chemotherapy , disease progression following platinum-containing chemotherapy within 12 months neoadjuvant adjuvant treatment platinum-containing chemotherapy . ( 1.7 ) single agent treatment patients bacillus calmette-guerin ( bcg ) -unresponsive , high-risk , non-muscle invasive bladder cancer ( nmibc ) carcinoma situ ( cis ) without papillary tumors ineligible elected undergo cystectomy . ( 1.7 ) microsatellite instability-high mismatch repair deficient cancer treatment adult pediatric patients unresectable metastatic microsatellite instability-high ( msi-h ) mismatch repair deficient ( dmmr ) solid tumors , determined fda-approved test , progressed following prior treatment satisfactory alternative treatment options . ( 1.8 , 2.1 ) microsatellite instability-high mismatch repair deficient colorectal cancer ( crc ) treatment patients unresectable metastatic msi-h dmmr colorectal cancer ( crc ) determined fda-approved test . ( 1.9 , 2.1 ) gastric cancer combination trastuzumab , fluoropyrimidine- platinum-containing chemotherapy , first-line treatment adults locally advanced unresectable metastatic her2-positive gastric gastroesophageal junction ( gej ) adenocarcinoma whose tumors express pd-l1 ( cps ≥1 ) determined fda-approved test . ( 1.10 ) combination fluoropyrimidine- platinum-containing chemotherapy , first-line treatment adults locally advanced unresectable metastatic her2-negative gastric gastroesophageal junction ( gej ) adenocarcinoma . ( 1.10 ) esophageal cancer treatment patients locally advanced metastatic esophageal gastroesophageal junction ( gej ) ( tumors epicenter 1 5 centimeters gej ) carcinoma amenable surgical resection definitive chemoradiation either : combination platinum- fluoropyrimidine-based chemotherapy , single agent one prior lines systemic therapy patients tumors squamous cell histology express pd-l1 ( cps ≥10 ) determined fda-approved test . ( 1.11 , 2.1 ) cervical cancer combination chemoradiotherapy , treatment patients figo 2014 stage iii-iva cervical cancer . ( 1.12 ) combination chemotherapy , without bevacizumab , treatment patients persistent , recurrent , metastatic cervical cancer whose tumors express pd-l1 ( cps ≥1 ) determined fda-approved test . ( 1.12 , 2.1 ) single agent treatment patients recurrent metastatic cervical cancer disease progression chemotherapy whose tumors express pd-l1 ( cps ≥1 ) determined fda-approved test . ( 1.12 , 2.1 ) hepatocellular carcinoma ( hcc ) treatment patients hcc secondary hepatitis b received prior systemic therapy pd-1/pd-l1-containing regimen . ( 1.13 ) biliary tract cancer ( btc ) combination gemcitabine cisplatin , treatment patients locally advanced unresectable metastatic biliary tract cancer . ( 1.14 ) merkel cell carcinoma ( mcc ) treatment adult pediatric patients recurrent locally advanced metastatic merkel cell carcinoma . ( 1.15 ) renal cell carcinoma ( rcc ) combination axitinib , first-line treatment adult patients advanced rcc . ( 1.16 ) combination lenvatinib , first-line treatment adult patients advanced rcc . ( 1.16 ) adjuvant treatment patients rcc intermediate-high high risk recurrence following nephrectomy , following nephrectomy resection metastatic lesions . ( 1.16 ) endometrial carcinoma combination carboplatin paclitaxel , followed keytruda single agent , treatment adult patients primary advanced recurrent endometrial carcinoma . ( 1.17 ) combination lenvatinib , treatment adult patients advanced endometrial carcinoma mismatch repair proficient ( pmmr ) msi-h determined fda-approved test , disease progression following prior systemic therapy setting candidates curative surgery radiation . ( 1.17 , 2.1 ) single agent , treatment adult patients advanced endometrial carcinoma msi-h dmmr , determined fda-approved test , disease progression following prior systemic therapy setting candidates curative surgery radiation . ( 1.17 , 2.1 ) tumor mutational burden-high ( tmb-h ) cancer treatment adult pediatric patients unresectable metastatic tumor mutational burden-high ( tmb-h ) [ ≥10 mutations/megabase ( mut/mb ) ] solid tumors , determined fda-approved test , progressed following prior treatment satisfactory alternative treatment options . 1 ( 1.18 , 2.1 ) limitations : safety effectiveness keytruda pediatric patients tmb-h central nervous system cancers established . cutaneous squamous cell carcinoma ( cscc ) treatment patients recurrent metastatic cscc locally advanced cscc curable surgery radiation . ( 1.19 ) triple-negative breast cancer ( tnbc ) treatment patients high-risk early-stage tnbc combination chemotherapy neoadjuvant treatment , continued single agent adjuvant treatment surgery . ( 1.20 ) combination chemotherapy , treatment patients locally recurrent unresectable metastatic tnbc whose tumors express pd-l1 ( cps ≥10 ) determined fda approved test . ( 1.20 , 2.1 ) adult classical hodgkin lymphoma adult primary mediastinal large b-cell lymphoma : additional dosing regimen 400 mg every 6 weeks additional recommended 400 mg every 6 weeks classical hodgkin lymphoma primary mediastinal large b-cell lymphoma adults . 2 ( 1.21 , 2.2 ) 1 indication approved accelerated approval based tumor response rate durability response . continued approval indication may contingent upon verification description benefit confirmatory trials . 2 indication approved accelerated approval based pharmacokinetic data , relationship exposure efficacy , relationship exposure safety . continued approval dosing may contingent upon verification description benefit confirmatory trials .",
    "contraindications": "melanoma : 200 mg every 3 weeks 400 mg every 6 weeks ; 2 mg/kg ( 200 mg ) every 3 weeks pediatrics . ( 2.2 ) nsclc : 200 mg every 3 weeks 400 mg every 6 weeks . ( 2.2 ) mpm : 200 mg every 3 weeks 400 mg every 6 weeks . ( 2.2 ) hnscc : 200 mg every 3 weeks 400 mg every 6 weeks . ( 2.2 ) chl pmbcl : 200 mg every 3 weeks 400 mg every 6 weeks adults ; 2 mg/kg ( 200 mg ) every 3 weeks pediatrics . ( 2.2 ) urothelial cancer : 200 mg every 3 weeks 400 mg every 6 weeks . ( 2.2 ) msi-h dmmr cancer : 200 mg every 3 weeks 400 mg every 6 weeks adults ; 2 mg/kg ( 200 mg ) every 3 weeks pediatrics . ( 2.2 ) msi-h dmmr crc : 200 mg every 3 weeks 400 mg every 6 weeks . ( 2.2 ) gastric cancer : 200 mg every 3 weeks 400 mg every 6 weeks . ( 2.2 ) esophageal cancer : 200 mg every 3 weeks 400 mg every 6 weeks . ( 2.2 ) cervical cancer : 200 mg every 3 weeks 400 mg every 6 weeks . ( 2.2 ) hcc : 200 mg every 3 weeks 400 mg every 6 weeks . ( 2.2 ) btc : 200 mg every 3 weeks 400 mg every 6 weeks . ( 2.2 ) mcc : 200 mg every 3 weeks 400 mg every 6 weeks adults ; 2 mg/kg ( 200 mg ) every 3 weeks pediatrics . ( 2.2 ) rcc : 200 mg every 3 weeks 400 mg every 6 weeks single agent adjuvant setting , advanced setting either : axitinib 5 mg orally twice daily lenvatinib 20 mg orally daily . ( 2.2 ) endometrial carcinoma : 200 mg every 3 weeks 400 mg every 6 weeks combination carboplatin paclitaxel regardless mmr msi status , combination lenvatinib 20 mg orally daily pmmr msi-h tumors , single agent msi-h dmmr tumors . ( 2.2 ) tmb-h cancer : 200 mg every 3 weeks 400 mg every 6 weeks adults ; 2 mg/kg ( 200 mg ) every 3 weeks pediatrics . ( 2.2 ) cscc : 200 mg every 3 weeks 400 mg every 6 weeks . ( 2.2 ) tnbc : 200 mg every 3 weeks 400 mg every 6 weeks . ( 2.2 ) administer keytruda intravenous infusion 30 minutes dilution . ( 2.4 ) full prescribing information modifications preparation instructions . ( 2.3 , 2.4 )",
    "warningsAndPrecautions": "keytruda injection ( clear slightly opalescent , colorless slightly yellow solution ) : carton containing one 100 mg/4 ml ( 25 mg/ml ) , single-dose vial ( ndc 0006-3026-02 ) carton containing two 100 mg/4 ml ( 25 mg/ml ) , single-dose vials ( ndc 0006-3026-04 )",
    "adverseReactions": "none .",
    "indications_original": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy, or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer. ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.",
    "contraindications_original": "Melanoma: 200 mg every 3 weeks or 400 mg every 6 weeks; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics. ( 2.2 ) NSCLC: 200 mg every 3 weeks or 400 mg every 6 weeks. ( 2.2 ) MPM: 200 mg every 3 weeks or 400 mg every 6 weeks. ( 2.2 ) HNSCC: 200 mg every 3 weeks or 400 mg every 6 weeks. ( 2.2 ) cHL or PMBCL: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics. ( 2.2 ) Urothelial Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks. ( 2.2 ) MSI-H or dMMR Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics. ( 2.2 ) MSI-H or dMMR CRC: 200 mg every 3 weeks or 400 mg every 6 weeks. ( 2.2 ) Gastric Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks. ( 2.2 ) Esophageal Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks. ( 2.2 ) Cervical Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks. ( 2.2 ) HCC: 200 mg every 3 weeks or 400 mg every 6 weeks. ( 2.2 ) BTC: 200 mg every 3 weeks or 400 mg every 6 weeks. ( 2.2 ) MCC: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics. ( 2.2 ) RCC: 200 mg every 3 weeks or 400 mg every 6 weeks as a single agent in the adjuvant setting, or in the advanced setting with either: axitinib 5 mg orally twice daily or lenvatinib 20 mg orally once daily. ( 2.2 ) Endometrial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks in combination with carboplatin and paclitaxel regardless of MMR or MSI status, or in combination with lenvatinib 20 mg orally once daily for pMMR or not MSI-H tumors, or as a single agent for MSI-H or dMMR tumors. ( 2.2 ) TMB-H Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics. ( 2.2 ) cSCC: 200 mg every 3 weeks or 400 mg every 6 weeks. ( 2.2 ) TNBC: 200 mg every 3 weeks or 400 mg every 6 weeks. ( 2.2 ) Administer KEYTRUDA as an intravenous infusion over 30 minutes after dilution. ( 2.4 ) See Full Prescribing Information for dosage modifications for adverse reactions and preparation and administration instructions. ( 2.3 , 2.4 )",
    "warningsAndPrecautions_original": "KEYTRUDA injection (clear to slightly opalescent, colorless to slightly yellow solution):\n                  Carton containing one 100 mg/4 mL (25 mg/mL), single-dose vial (NDC 0006-3026-02)Carton containing two 100 mg/4 mL (25 mg/mL), single-dose vials (NDC 0006-3026-04)",
    "adverseReactions_original": "None."
}